You are here

Case Report: Meningo-radiculitis with bilateral optic neuropathy associated with ipilimumab

Presentation by William Boisseau at the TAO Congress on 19/20 November 2015


The patient is a 27-year-old woman who has renal carcinoma with translocation TFEB. The TAP CT scan reveals metastases in the lung and retroperitoneal lymph nodes. After right nephrectomy has been performed, she receives chemotherapy: the first-line treatment consists of sunitinib, which is stopped due to hepatic toxicity and progression, the second-line treatment of pazopanib, which is stopped due to tumoral progression, the third-line treatment of everolimus, which is stopped due to progression, and the fourth-line treatment of the CTLA-4 inhibitor ipilimumab.

The patient manifests with severe and bilateral visual loss as well as diffuse pain in the legs. William Boisseau reviews the patient’s history of meningo-radiculitis with bilateral optic neuropathy associated with ipilimumab, followed by comments from the expert panel.

This case report is part of the programme “AERIO meets the experts” by the French Association of Residents in Oncology (AERIO) in collaboration with an expert panel (Dr. Mario Dicato, Luxembourg Medical Center, Luxembourg; Dr. Richard Gralla, A. Einstein School of Medicine, New York, USA; Dr. Jeffrey Crawford, Duke Cancer Center, Durham, USA; Dr. Pere Gascon, Hospital Clinic, Barcelona).

William Boisseau, Intern, Pitié-Salpêtrière Hospital, Paris, France

Search this site

Featured videos

Free access to ebooks on cachexia and CINV


Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

Cancer cachexia: mechanisms and progress in treatment


Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo